Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21832966 | 0.94 | ADORA2A (0.79) | ADORA2AADORA1 | |
| SCHEMBL21832443 | 0.90 | ADORA2A (0.78) | ADORA2AADORA1 | |
| SCHEMBL21833248 | 0.90 | ADORA2A (0.65) | ADORA2AADORA1 | |
| SCHEMBL21832351 | 0.89 | ADORA2A (0.68) | ADORA2AADORA1 | |
| SCHEMBL21833282 | 0.89 | ADORA2A (0.65) | ADORA2AADORA1 | |
| SCHEMBL21833374 | 0.88 | ADORA2A (0.67) | ADORA2AADORA1 | |
| SCHEMBL21833941 | 0.88 | ADORA2A (0.89) | ADORA2AADORA1 | |
| SCHEMBL21833392 | 0.87 | ADORA2A (0.64) | ADORA2AADORA1 | |
| SCHEMBL21833542 | 0.86 | ADORA2A (0.66) | ADORA2AADORA1 | |
| SCHEMBL21832696 | 0.85 | ADORA2A (0.62) | ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230098694-A1 | NON BRAIN PENETRANT A2A INHIBITORS AND METHODS FOR USE IN THE TREATMENT OF CANCERS | ITEOS BELGIUM S A (BE) | 2023-03-30 | — | — | US | disclosed |
| US-11427594-B2 | Non brain penetrant A2A inhibitors and methods for use in the treatment of cancers | iTeos Belgium SA (BE) | 2022-08-30 | — | — | US | disclosed |
| US-20200102319-A1 | NON BRAIN PENETRANT A2A INHIBITORS AND METHODS FOR USE IN THE TREATMENT OF CANCERS | iTeos Belgium SA (BE) | 2020-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200102319-A1 | NON BRAIN PENETRANT A2A INHIBITORS AND METHODS FOR USE IN THE TREATMENT OF CANCERS | ADORA2A, ADORA2B, ADORA1 | ADORA2A 1/4885ADORA1 3/4885 |
| US-11427594-B2 | Non brain penetrant A2A inhibitors and methods for use in the treatment of cancers | ADORA2A, ADORA2B, ADORA1 | ADORA2A 1/4885ADORA1 3/4885 |
| US-20230098694-A1 | NON BRAIN PENETRANT A2A INHIBITORS AND METHODS FOR USE IN THE TREATMENT OF CANCERS | ADORA2A, ADORA2B, ADORA1 | ADORA2A 1/4885ADORA1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.